Clindamycin: Difference between revisions
imported>David E. Volk mNo edit summary |
mNo edit summary |
||
| (6 intermediate revisions by 5 users not shown) | |||
| Line 1: | Line 1: | ||
{{subpages}} | {{subpages}} | ||
{{Image|Clindamycin structure.jpg|right|200px|Clindamycin, an antibiotic drug.}} | |||
'''Clindamycin''' is an [[antibiotic]] drug, in the [[lincomycin]] class, used to treat infections. It is a semisynthetic version of lincomycin. It is used to treat [[streptococci]], [[pneumococci]] and [[staphylococci]]. | '''Clindamycin''' is an [[antibiotic]] drug, in the [[lincomycin]] class, used to treat infections. It is a semisynthetic version of lincomycin. It is used to treat [[streptococci]], [[pneumococci]] and [[staphylococci]]. | ||
| Line 7: | Line 7: | ||
The IUPAC chemical name of clindamycin is (2S,4R)-N-[2-chloro-1-[(2R,3R,4S,5R,6R)-3,4,5-trihydroxy-6-methylsulfanyloxan-2-yl]propyl]-1-methyl-4-propylpyrrolidine-2-carboxamide. It has chemical formula C<sub>18</sub>H<sub>33</sub>ClN<sub>2</sub>O<sub>5</sub>S, giving it a molecular mass of 424.9830 g/mol. | The IUPAC chemical name of clindamycin is (2S,4R)-N-[2-chloro-1-[(2R,3R,4S,5R,6R)-3,4,5-trihydroxy-6-methylsulfanyloxan-2-yl]propyl]-1-methyl-4-propylpyrrolidine-2-carboxamide. It has chemical formula C<sub>18</sub>H<sub>33</sub>ClN<sub>2</sub>O<sub>5</sub>S, giving it a molecular mass of 424.9830 g/mol. | ||
== Usage == | |||
Clindamycin, a relatively old drug, is being found valuable in the treatment of methicillin-resistant ''[[Staphylococcus aureus]]'' (MRSA), an organism that causes significant [[nosocomial]] infection, which, increasingly, is considered a [[medical error]] for which third-party payor will not reimburse. While improvement in infection control technique are key to preventing hospital-acquired MRSA infection, there will be infections and they will need to be treated. <ref name=Gorwitz>{{citation | |||
| author = Gorwitz RJ, Jernigan DB, Powers JH, Jernigan JA, and Participants in the CDC Convened | |||
Experts’ Meeting on Management of MRSA in the Community | |||
| id = Gorwitz | |||
| title = Strategies for clinical management of MRSA in the community: Summary of an experts’ meeting convened by the Centers for Disease Control and Prevention | |||
| year = 2006 | |||
| url = http://www.cdc.gov/ncidod/dhqp/ar_mrsa_ca.html}}</ref> | |||
Clindamycin may be associated with a higher incidence of ''[[Clostridium difficile]]''-associated disease (CDAD), including [[pseudomembranous enterocolitis]]. Additional laboratory testing may be appropriate to evaluate the possibility of induced clindamycin resistance in MRSA. <ref>Gorwitz, p. 7</ref> Whenever clindamycin is used, especially in oral form with outpatients, patients should be cautioned to report, immediately, episodes of diarrhea. | |||
== Synonyms and brand names == | == Synonyms and brand names == | ||
''Synonyms'' | ''Synonyms'' | ||
| Line 39: | Line 49: | ||
* Evoclin® | * Evoclin® | ||
* Sobelin® | * Sobelin® | ||
==References== | |||
<references/>[[Category:Suggestion Bot Tag]] | |||
Latest revision as of 16:00, 29 July 2024
Clindamycin is an antibiotic drug, in the lincomycin class, used to treat infections. It is a semisynthetic version of lincomycin. It is used to treat streptococci, pneumococci and staphylococci.
Chemistry
The IUPAC chemical name of clindamycin is (2S,4R)-N-[2-chloro-1-[(2R,3R,4S,5R,6R)-3,4,5-trihydroxy-6-methylsulfanyloxan-2-yl]propyl]-1-methyl-4-propylpyrrolidine-2-carboxamide. It has chemical formula C18H33ClN2O5S, giving it a molecular mass of 424.9830 g/mol.
Usage
Clindamycin, a relatively old drug, is being found valuable in the treatment of methicillin-resistant Staphylococcus aureus (MRSA), an organism that causes significant nosocomial infection, which, increasingly, is considered a medical error for which third-party payor will not reimburse. While improvement in infection control technique are key to preventing hospital-acquired MRSA infection, there will be infections and they will need to be treated. [1]
Clindamycin may be associated with a higher incidence of Clostridium difficile-associated disease (CDAD), including pseudomembranous enterocolitis. Additional laboratory testing may be appropriate to evaluate the possibility of induced clindamycin resistance in MRSA. [2] Whenever clindamycin is used, especially in oral form with outpatients, patients should be cautioned to report, immediately, episodes of diarrhea.
Synonyms and brand names
Synonyms
- Clindamycin HCl
- Clindamicina
- Clindamycin Hydrochloride
- Clindamycin Phosphate
- Clindamycine
- Clindamycine
- Clindamycinum
Brand Names
- Chlolincocin®
- Cleocin®
- Cleocin HCl®
- Cleocin Pediatric®
- Cleocin Phosphate®
- Cleocin T®
- Cleocin T® Gel
- Cleocin T® Lotion
- Cleocin T® Topical Solution
- Clinda-Derm®
- Clindagel®
- Clindesse®
- Clindets®
- Clinimycin®
- Dalacin®
- Dalacin C®
- Dalacin C® Flavored Granules
- Dalacin C® Phosphate
- Dalacin T® Topical Solution
- Evoclin®
- Sobelin®
References
- ↑ Gorwitz RJ, Jernigan DB, Powers JH, Jernigan JA, and Participants in the CDC Convened Experts’ Meeting on Management of MRSA in the Community (2006), Strategies for clinical management of MRSA in the community: Summary of an experts’ meeting convened by the Centers for Disease Control and Prevention, Gorwitz
- ↑ Gorwitz, p. 7